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Abstract: In the adult population, glioblastoma multiforme is one of the most common primary brain tumors encoun-
tered. Unfortunately, this highly malignant tumor represents over 50% of all types of primary central nervous system 
gliomas. The vast majority of GBMs develops quite rapidly without clinical, radiological, or morphologic evidence of 
a less malignant precursor lesion (primary or de novo GBMs), as compared to secondary GBMs that develop slowly 
by progression from diffuse low-grade astrocytomas. These GBM subtypes must be kept in mind because they may 
constitute distinct disease entities. Even though they look histologically quite similar, they likely involve different 
genetic alterations and signaling pathways. Decades of surgical therapy, radiotherapy, and chemotherapy have failed 
to drastically change survival. Clearly, we do not fully understand this tumor; however, the exciting genetic revolution 
in glioma research over the past decade is providing a promising outlook for exploring this tumor at the genetic level. 
Science has begun to elucidate the numerous genetic alterations and critical signaling pathways, and it has opened new 
exciting areas of research such as glioma stem cell biology and neoangiogenesis. This work has already begun to 
improve our understanding of GBM cell proliferation, migration, and invasion. Indeed, exciting novel targeted therapies 
are making their way to clinical trials based on this increased knowledge. This review provides the current understanding 
of GBM oncogenomics, signaling pathways, and glioma stem cell biology and discusses the potential new therapeutic 
targets on the horizon.
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Introduction
In the adult population, glioblastoma multiforme (GBM), is a common and one of the most malignant 
primary brain tumors, representing up to 50% of all primary brain gliomas.
1 The majority of GBMs 
develops rapidly without clinical, radiological, or morphologic evidence of a less malignant precursor 
tumor (primary or de novo GBMs) (Table 1). Secondary GBMs develop slowly by progression from 
low-grade or anaplastic astrocytomas. Even though they look similar histologically, primary and 
secondary GBMs appear to constitute distinct disease entities—they affect different age groups, clini-
cally progress at different rates, and involve different genetic alterations and signaling pathways 
(Table 1).
2,3
Decades of surgical therapy, radiotherapy, and chemotherapy have failed to drastically change sur-
vival for GBM. In a recent meta-analysis of 12 randomized clinical trials, the overall survival rate of 
patients with malignant gliomas was 40% at one year and only slightly higher (46%) after the addition 
of adjuvant therapies.
4 We do not have a sufﬁ  cient understanding of this tumor’s biology; however, the 
recent genetic revolution in glioma research is providing a promising outlook for exploring this tumor 
at a more in-depth level. Science has now begun to elucidate a protean network of genetic alterations 
and critical signaling pathways responsible for GBM initiation, migration, and invasion, opening the 
door for novel, molecular-based, targeted therapies (Fig. 1). Recent exciting work has introduced the 
potential for therapeutic targeting of glioma stem cells and tumor neoangiogenic pathways. We now 
realize that many key pathways are in play. Combination therapies directed at multiple sites have now 
become common in clinical trials. GBM research is making signiﬁ  cant strides forward and exciting 40
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               Astrocytes, tumor stem cells 
Pilocytic astrocytoma (WHO I)
Low-grade astrocytoma (WHO II)
p53 mutation (50%) 
Anaplastic astrocytoma (WHO III)
p53 mutation (50%) 
p14ARF   methylated more (same%) 
MGMT methylated (75%) 
Secondary GBM (WHO IV) (10%)     Primary GBM (WHO IV) (90%)
LOH 10q (60%)                                                  Loss entire chromosome 10 (70%) 
EGFR amplification (10%)                                  EGFR amplification (40%–60%) 
p16INK4a    deletion (20%)                                  p16 INK4a  deletion (30%) 
p14ARF    methylated more (same%)                  p14ARF  (same%) 
p53  mutation,  codon  248/273  (65%)          p53  mutation,  all  exons  (30%) 
PTEN mutation (5%)                                          PTEN mutation (25%) 
RB1 methylated (40%)                                       RB1 methylated (15%) 
MGMT methylated (75%)                                   MGMT methylated (36%) 
*Adapted from [122]
Table 1. Major genetic alterations in primary and secondary GBM initiation and progression.*
novel targeted therapies are making their way to 
clinical trials. There is real hope that the near future 
will bring improved survivals to patients afﬂ  icted 
with this universally fatal disease.
Oncogenomics and Other 
Genetic Events
Oncogenomics
Comprehensive genetic screens of GBM have 
shown that genetic loss is scattered across the entire 
genome, affecting nearly all chromosomes at 
frequencies ranging from 2% to 80%. Particularly 
common regions of loss include areas on 1p, 6q, 
9p, 10p, 10q, 13q, 14q, 15q, 17p, 18q, 19q, 22q, 
and Y.
5–10 Loss of heterozygosity (LOH) on 
chromosome 10 is the most frequent genetic 
alteration in GBM, occurring in 60%–80% of cases.
11 
Many GBMs appear to have lost an entire copy of 
chromosome 10, but several LOH studies have 
suggested at least three distinct loci to be deleted 
(e.g., 10p14–p15, 10q23–24, distal to 10q25). This 
strongly suggests the presence of tumor suppressor 
genes (TSGs) at these loci.
11–13 Most primary 
GBMs show loss of the entire chromosome, 
whereas secondary GBMs with LOH show partial 
loss of 10q.
14 Allelic losses on 1p and 7q have also 
been seen in GBM, but at lower frequencies. Loss 
of 1p occurs in up to 31% of GBMs
8,15,16 and in 
combination with 19q loss, may indicate a better 
prognosis and response to therapy.
16–18 Loss of 41
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Figure 1. Signaling pathways implicated in GBM. Oncogenes are in gray circles. Tumor suppressor genes are in black boxes. Black dots 
are phosphate groups. Equal signs represent protein-protein interactions.42
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7q is seen in 9% to 12% of GBMs.
8,15 Loss of gene 
dosage from numerous genomic alterations has 
been documented in GBM, such as entire chromo-
somal loss, partial chromosomal loss, speciﬁ  c 
allelic loss, inactivating mutations, and promoter 
methylation. To date, few speciﬁ  c TSGs have been 
deﬁ  nitively implicated in GBM. It is assumed that 
many of these losses represent loss of speciﬁ  c TSGs 
with direct effects on gliomagenesis; however, 
some of these losses likely represent the inherent 
genomic instability that develops in tumor cells.
Gains of gene expression due to genetic altera-
tions at the genomic level have also been demon-
strated in GBM in the form of duplication of entire 
chromosomes, intra-chromosomal ampliﬁ  cation 
of speciﬁ  c alleles, extra-chromosomal ampliﬁ  ca-
tion (often in the form of double minutes [dmins]), 
and activating mutations.
10,19,20 These forms of 
increased gene expression (oncogenic) occur much 
less frequently than losses of gene expression as 
noted above. Clearly, the most common oncogenic 
event is ampliﬁ  cation of the epidermal growth 
factor receptor (EGFR) gene on chromosome 7, 
often in the form of dmins.
20,21 A few other genes 
have been clearly implicated as oncogenes (Table 2 
and Fig. 1). This collection of oncogenomic events 
is daunting and difﬁ  cult to decipher. Recently 
developed methods for performing genome-wide 
screens will greatly help to better deﬁ  ne these 
events with respect to tumor initiation, progression, 
migration, invasion, and survival in preclinical 
models.
Many genetic alterations, such as gene ampli-
fication or deletion, represent direct glioma-
inducing events, whereas others indirectly affect 
gliomagenesis through processes such as DNA 
instability. The overall mutation rate in somatic 
human cells is about 1.4 × 10
10 nucleotides per 
cell division, translating into about one mutant 
gene per cell during an individual’s lifespan. The 
low spontaneous mutation rate in normal cells 
cannot account for the large mutation rate in 
GBM. In addition to many of the genetic events 
noted above, gliomagenesis likely involves errors 
in DNA replication, DNA repair, chromosomal 
segregation, and alteration of numerous signaling 
cascades not directly attributed to genomic muta-
tions. This collection of genetic and cellular 
alterations gives rise to a tumor cell phenotype, 
previously described as a “mutator phenotype.”
23 
Central to this mutator phenotype are DNA repair 
mechanisms. There are at least four major DNA 
repair pathways that may go awry in GBMs, 
including nucleotide excision repair, base exci-
sion repair, mismatch repair, and direct reversal 
of lesions in recombination.
23,24 As one example, 
elevated levels of the DNA repair enzyme 
O6-methylguanine-DNA methyltransferase 
(MGMT) have been demonstrated in GBM.
25 This 
would confer resistance towards alkylating 
agents. Its expression also correlates with temo-
zolomide (TMZ) treated GBMs.
26 MGMT 
speciﬁ  cally removes promutagenic alkyl groups 
from the O6 position of guanine in DNA. Therefore, 
MGMT protects cells against carcinogenesis 
induced by alkylating agents. Repair of O6-alkyl-
guanine adducts by tumor cells has been impli-
cated in drug resistance, since it reduces the 
cytotoxicity of alkylating chemotherapeutic 
agents.
27 Loss of MGMT expression may be 
caused by methylation of promoter CpG islands, 
which has been observed in gliomas.
28,29 MGMT 
promoter methylation has been detected in 75% 
of secondary GBMs, much more than in primary 
GBMs (36%).
29 Interestingly, the majority of 
low-grade gliomas with MGMT methylation 
(92%) contain a mutation in the tumor suppressor 
gene p53, whereas only 39% of those without 
MGMT methylation carry a p53 mutation.
29 Fur-
thermore, G:C to A:T transition mutations at CpG 
sites are signiﬁ  cantly more frequent in low-grade 
gliomas with MGMT methylation (58%) than in 
those without (11%).
29 This association with 
increased frequency of p53 mutations suggests 
that loss of MGMT expression due to promoter 
methylation frequently occurs at an early stage 
in the pathway leading to secondary GBMs.
Despite the development of a mutator pheno-
type and the plethora of genetic alterations it likely 
entails, there are a discreet number of genetic 
events and signaling pathways that appear to be 
central to GBM initiation, migration, invasion, and 
survival (Fig. 1). Growth factor pathways, such as 
epidermal and vascular epithelial growth factor 
receptors (EGFR, VEGFR) play a signiﬁ  cant role 
glioma cell proliferation, migration, and neovas-
cularization. Ras plays a critical intracellular 
crossroad between numerous pathways, allowing 
Ras to inﬂ  uence most tumor cell behaviors. P53 
and RB1 pathways are often intimately connected 
in oncology. They both play pivotal roles in regu-
lating cell cycling in response to stimuli for cellular 
repair or cellular growth. Perhaps due to its 
homology to proteins that interact with plasma 43
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Table 2. Genetic alterations in GBM.
Gene Chromosome Mechanism Frequency Ref.
Multiple 1p, 6q, 7q, losses 2%–75% 5–7, 9, 123
9p, 10p, 10q, 8, 10, 15, 16
13q, 14q, 15q,
17p, 18q, 19q,
22q, Y
Multiple 1q, 3q, 4p,
4q, 7p, 7q,
12q, 13q, 19 gains up to 80% 10, 19, 20
CASP8 2q33 promoter methylation nd 124
KLF6 10p15 inactivating mutation 12% 125
MGMT 10q26 methylated up to 75% 28, 29, 126
NF1 17q11 inactivating mutation nd 38
NF2 22q12 deleted nd
p16 and p14 9p21 homozygous deletion up to 50% 61, 63, 127–129
p16
INK4a 9p21 deleted, methylated 40%–60% 60, 71–74
p14
ARF 9p21 deleted, methylated nd 29
p53 17p13 inactivating mutation 30%–60% 60, 127, 130, 131
PTEN 10q23 inactivating mutation 5%–40% 80, 81, 88, 89, 132
RB1 13q14 inactivating mutation 30% 61, 128, 133
RUNX3 1p36 methylated nd 134
TES 7q31 methylated nd 134
TMS1/ASC 16p11 methylated 20% 135
CDK4 12q14 ampliﬁ  ed nd 19, 20
CDK6 7q21 ampliﬁ  ed nd 20
COL4A2 13q34 ampliﬁ  ed nd 20
CSE1L 20q13 ampliﬁ  ed up to 57% 19
EGRF 7p21 ampliﬁ  ed (often dmins) 40%–60% 19, 21, 22
EGFRvIII 7p21 ampliﬁ  ed 20%–30% 22
ESR nd ampliﬁ  ed up to 36% 19
FGR 1p35 ampliﬁ  ed up to 36% 19
GLI 12q13 ampliﬁ  ed nd 19, 136
MDM2 12q15 ampliﬁ  ed 10% 19,66
MYC 8q24 ampliﬁ  ed nd 19
MYCN 2p24 ampliﬁ  ed nd 19
NRAS 1p13 ampliﬁ  ed nd 19
PDGFRA 4q12 ampliﬁ  ed up to 65% 19, 20
PGY1 7q21 ampliﬁ  ed up to 36% 19
PIK3CA 3q26 activating mutation nd 136
SLA/LP 4p15 ampliﬁ  ed nd 20
STIM2 4p15 ampliﬁ  ed nd 20
TNFSF13B 13q33 ampliﬁ  ed 8% 2044
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membrane adhesions and the cytoskeletal network, 
PTEN-related signaling is often implicated in 
cellular migration in addition to its connection to 
the Ras cascade.
Signaling Pathways
Growth factor tyrosine kinase 
receptor pathway
In GBM, aberrant EGFR and other tyrosine kinase 
receptor autocrine signaling pathways may be the 
most often cited pathways. These lead to robust 
alterations in cellular development, proliferation, 
migration, and tumor-induced neovascularization. 
Growth factor signaling mediated by ligands like 
EGF activates an intricately complex network of 
intracellular cascades modulated by G-protein-
coupled receptors and second messengers which 
converge at multiple sites, one of which is Ras. 
These clearly play a central role in brain glioma-
genesis. EGFR ampliﬁ  cation and overexpression 
occur in 40%–60% of primary GBMs, and rarely 
in secondary GBMs.
2,21,30,31 Ampliﬁ  cation of the 
EGFR gene is often associated with structural 
alterations in the gene. Seven major mutated vari-
ants of EGFR have been identified, the most 
common being variant III (EGFRvIII), also called 
de2–7EGFR or ρEGFR which is present in 
20%–50% of GBMs with EGFR ampliﬁ  cation.
32–35 
EGFRvIII results from a nonrandom 801-bp in-
frame deletion of exons 2–7 of the EGFR gene that 
occurs at the genomic level leading to expression 
of aberrant transcripts and proteins.
34 This mutated 
protein lacks a portion of the extracellular ligand-
binding domain as a result of genomic deletions, 
resulting in a constitutively autophosphorylated 
receptor, albeit at a lower level than wild type.
36 
In addition to enhancing growth, proliferation, 
migration, and tumor neovascularization, this 
truncated receptor also confers resistance to che-
motherapies such as cisplatin through modulation 
of Bcl-XL and caspases in cell death pathways.
37 
Multiple murine glioma models have conﬁ  rmed 
the importance of this aberrant growth factor sig-
naling in gliomagenesis.
38–40 Platelet derived 
growth factor receptor (PDGFR) is a similar recep-
tor expressed in most types of gliomas,
41 while 
EGFR is expressed mainly in GBM.
42 PDGFR 
signals through phosphoinositide 3-kinase (PI3K) 
and phospholipase C gamma (PLC-γ).
43
Ras signaling
In sporadic GBMs, speciﬁ  c mutations affecting 
Ras have not been detected; however, high levels 
of Ras guanosine triphosphate (GTP) have been 
documented in cell lines and primary tumors, sug-
gesting that this signaling pathway is activated by 
upstream factors such as receptor tyrosine kinase 
activation (e.g. EGFR or PDGFR).
44 Another 
major way of activating this pathway is via the 
loss of neuroﬁ  bromin function, the protein product 
of the large neuroﬁ  bromatosis 1 (NF1) gene. NF1 
has been considered a mutational hot spot in the 
human genome.
38 Germline mutations and loss-
of-function mutations have been seen in the 
disease, which includes optic nerve gliomas, 
astrocytomas, and GBMs.
45–47 NF1 negatively 
regulates Ras as an exchange factor converting 
Ras-GTP to Ras-GDP by its GTPase-activating 
(Ras-GAP) domain.
38 Ras-GTP is downstream of 
growth factor receptors at a major signal transduc-
tion crossroad, translating extrinsic messages into 
the Raf-MAPKK-ERK pathway or into either the 
PI3K-PKB or the PI3K-Rac-Rho pathway. These 
inﬂ  uence cell survival and migration. The PI3K-
Rac-Rho pathway is involved in cell motility and 
is negatively regulated by merlin, the protein 
product of the neuroﬁ  bromatosis type II (NF2) 
tumor suppressor gene that links the cytoskeleton 
to the membrane.
48
In mouse models of GBM, neither activated Ras 
nor Akt alone induce tumors; however, the 
combination of both activations can.
40 Similarly, 
mouse models deﬁ  cient in NF1 and p53 develop 
GBM-like tumors with all the characteristic 
features, including invasion, neovascularity, 
necrosis, and atypical astrocytes.
49
TGF-β signaling
Overexpression or altered signaling of growth 
factors and their respective pathways is a common 
theme in GBM. EGFR, VEGF, PDGR, and TGF 
have all been implicated in GBM. In response to 
TGF-β stimulation, two TβRI receptor-associated 
Smads, Smad2 and Smad3, become phosphorylated 
and activated. After activation, Smads form a het-
erodimeric complex with Smad4 and translocate 
to the nucleus to participate in activation of numer-
ous target genes that contribute to proliferation and 
neovascularization.
50 TGF-β appears to have alter-
native mechanisms for promoting tumorigenesis, 
either as a tumor suppressor gene, a mitogen, or an 45
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invasion-promoter. TGF-β can function as a tumor 
suppressor gene in GBM by inhibiting expression 
of cdks or downregulating cdk activity by inducing 
cdk inhibitors p15, p27, and Cip/WAF1/p21.
51,52 
Perhaps more interesting is that it can downregulate 
cell adhesion proteins, induce an epithelial to mes-
enchymal transition, and thereby, enhance cell 
migration and invasion.
53–55 TGF-β can alter col-
lagen synthesis, integran expression, cell adhesion 
to reconstituted basement membrane, and invasive-
ness in gliomas.
56,57 TGF-β1 and TβRII are 
expressed in GBM and not in normal brain or 
low-grade gliomas,
58 where expression levels are 
indirectly correlated with survival. TGF-β induces 
expression of PDGF-A, which may serve as the 
primary mediator of TGF-β growth stimulatory 
effects.
59 Instead of the standard Smad pathway 
that results in growth inhibition, TGF-β can deviate 
upstream of Smad to activate other mitogenic 
pathways implicated in GBM, including MAPK 
(Ras-Erk) and SAPK (Rho-JNK, TAK1-p38 
kinase). These pathways result in activation of dif-
ferent target genes leading to proliferation and 
transformation. Compared to the other commonly 
studied signaling pathways in GBM, TGF-β is a 
unique therapeutic target in that it may represent 
an important crosslink to various intracellular pro-
cesses. Unfortunately, its complex and sometimes 
opposing actions have made it difﬁ  cult to clearly 
understand when and how to target it.
p53-MDM2-p14
ARF pathway
The majority of malignant brain tumors, includ-
ing GBM, demonstrate inactivating mutations in 
either the p53 and/or retinoblastoma (RB) path-
ways.
60–63 These two pathways affect numerous 
cellular functions, but they are most intensely 
implicated in cell cycling regulation during times 
of cell repair or cell growth. They interact with 
each other via p21. P53 is a short-lived transcrip-
tion factor which is upregulated in response to 
cellular stress such as radiation exposure, DNA 
strand breaks, and toxins. It facilitates DNA 
repair by halting the cell cycle for repair enzymes 
to work, or if the damage is too great, it induces 
cell death. As an “apoptostat” protein, it sets a 
cell’s apoptotic threshold in response to speciﬁ  c 
endogenous and exogenous insults. Following 
DNA damage, p53 is activated and induces 
transcription of genes such as p21
Waf1/Cip1.
64,65 P53 
is stabilized by binding to p14
ARF and degraded 
by MDM2.
65 Secondary GBMs have a higher 
incidence of p53 mutations (65%), the majority 
of which are present in prior lower grade biop-
sies.
2,31 Ampliﬁ  cation of MDM2 is present in up 
to 10% of GBMs, and these all appear to be in 
primary GBMs that lack p53 mutations.
66 Loss of 
p14
ARF expression has often been seen in GBMs 
(76%), and this correlates with homozygous dele-
tion or promoter methylation of the p14
ARF gene.
67 
There is no difference in the overall frequency of 
p14
ARF alterations between primary and secondary 
GBMs, but p14
ARF promoter methylation is more 
frequent in secondary GBMs.
67 Analysis of mul-
tiple biopsies from the same patient reveals that 
p14
ARF methylation is present in up to a third of 
lower grade astrocytomas, suggesting an early 
event in secondary GBMs.
67
The type and distribution of p53 mutations may 
differ between GBM subtypes. In secondary 
GBMs, 57% of mutations are located in two hotspot 
codons 248 and 273, whereas in primary GBMs, 
mutations are more equally distributed through all 
exons.
2 Additionally, G:C to A:T mutations at CpG 
sites, especially in codons 248 and 273, appear to 
be an early event associated with malignant trans-
formation in the pathway to secondary GBMs. This 
discrepancy between GBM subtypes is unclear. 
The less speciﬁ  c pattern of p53 mutations may 
simply represent increased genomic instability.
RB1-p16
INK4a pathway
RB1 controls the transition from G1 into S phase 
of the cell cycle by inhibiting the action of elonga-
tion factor E2F1. The cyclin-dependent kinase 4 
(CDK4)/cyclin D1 complex phosphorylates the 
RB1 protein, thereby increasing release of the 
E2F1 transcription factor that activates genes 
involved in the G1 to S transition.
68 p16
INK4a binds 
to CDK4, inhibits the CDK4/cyclin D1 complex, 
and thus inhibits the G1 to S transition.
68 Inactivat-
ing mutations in RB1 or the upstream factor 
p16
INK4a (also called inhibitor of CDK4a), or acti-
vating mutations in the downstream factors CDK4 
or cyclin D, cause dysregulated control of E2F1. 
This leads to the expression of S-phase-related 
genes and uncontrolled cell cycling. Additionally, 
it leads to expression of anti-apoptotic genes like 
Bcl-2, causing uncontrolled cell proliferation.
69
The genetic locus INK4a/ARF on chromosome 
9p21 produces both p14
ARF and p16
INK4a by 
alternative splicing.
64 Since p16
INK4a negatively 46
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regulates CDK4 and p14
ARF (p19
ARF in mice) 
inhibits MDM2, blocking rapid ubiquitin-mediated 
decay of p53, simultaneous inactivation of both 
genes by a homozygous deletion dysregulates both 
the RB1 pathway and the p53 pathway. In other 
words, this single locus drives gliomagenesis. Up to 
50% of malignant human gliomas have homozygous 
deletions that span the reading frame of both genes.
63 
This is one of the most frequent genetic changes in 
GBM that is acquired during tumor progression. 
Most GBMs that retain an intact INK4a/ARF locus 
display mutations in other genes of the p53 and the 
RB pathways, leading to unchecked cell cycling and 
apoptotic resistance. As alluded to above, p16
INK4a 
is an inhibitor of CDK4, blocks CDK4-dependent 
phosphorylation of the RB protein
70 and acts as a 
negative regulator of cell proliferation. Different 
mechanisms have been reported for inactivation of 
the p16
INK4a gene in GBM, including homozygous 
deletion and hypermethylation of the promoter 
region.
71–74 In GBM, frequent promoter hypermeth-
ylation has been noted for p14
ARF and RB1.
75–77
Homozygous p16
INK4a deletions are more fre-
quent in primary than in secondary GBMs.
67,78 
However, there is no major difference in overall 
frequency of any p16
INK4a alteration (including 
homozygous deletion and promoter methylation) 
between these GBM subtypes.
67 Promoter methyla-
tion of the RB1 gene is more frequent in secondary 
(43%) than in primary GBMs (14%).
79 There is a 
correlation between loss of RB1 expression and 
promoter methylation of the RB1 gene in GBMs.
79 
RB1 promoter methylation is not detected in low 
grade and anaplastic astrocytomas, suggesting that 
this is a late event in astrocytoma progression.
79
PTEN/Akt-1 pathway
Mutations of the TSG phosphatase tensin homology 
(PTEN) on chromosome 10q23, also called 
MMAC1 and TEP1, occur frequently in familial 
developmental and cancer syndromes such as 
Cowden-Bannayan syndrome and Lhermitte-
Duclos disease.
80,81 Many of these syndromes 
include GBM as part of the clinical spectrum. 
PTEN contains a central catalytic phosphatase core 
domain that negatively regulates PI3K by dephos-
phorylating phosphatidylinositol-3,4,5 triphosphate 
(PIP3) and phosphatidylinositol-3,4 diphosphate 
(PIP2).
82 The N-terminus of PTEN is homologous 
to the cytoplasmic proteins tensin and auxilin, which 
interact with actin ﬁ  laments at focal adhesions and 
clathrin-coated vesicles. In the case of mutant 
PTEN, the elevated lipid second messenger PIP3 
is used by PI3K to hyperphosphorylate Akt (also 
known as protein kinase B [PKB]).
83 This modu-
lates the activity of proteins that play a critical role 
in cell survival, invasion, and proliferation.
84 The 
catalytic activity toward phosphoinositide sub-
strates is required for growth suppression, and 
PTEN-mediated growth inhibition is due to G1 cell 
cycle block rather than induction of apoptosis.
85 
The PTEN C2 domain binds phospholipid mem-
branes and mutations in this domain reduce PTEN’s 
membrane afﬁ  nity and ability to suppress growth 
and motility of GBM cells. Alternatively, tumors 
with an activated PTEN/Akt pathway may be sen-
sitive to mTOR inhibitors, such as rapamycin.
86
In GBM, deletions distal to 10q25 (distal to PTEN) 
cover DMBT1 and FGFR2 loci,
87 which suggest that 
acquisition of the GBM phenotype is associated with 
loss of other putative TSGs. The PTEN gene at 10q23 
is mutated in 5%–40% of GBMs.
68,80,86,88,89 PTEN 
mutations are almost exclusively seen in primary 
GBMs, but rarely in secondary GBMs.
2 PTEN homo-
zygous deletion is rare (2%).
90 Promoter methyla-
tion may be an alternative mechanism of loss of 
PTEN expression, but the signiﬁ  cance of PTEN 
methylation in the evolution of GBMs remains to be 
determined.
91 Nonsense mutations (12%) and dele-
tions or insertions leading to stop codons (32%) 
appear to be more equally distributed throughout the 
exons, whereas one-third are missense mutations 
leading to amino acid changes, preferentially located 
in exons 1–6, regions homologous to tensin, auxilin, 
and phosphatases.
2,92
Glioma stem cells
The concept of a cancer stem cell is not a recent 
phenomenon, but has only recently been extended 
to brain tumors and exploited as worthy of study 
for therapy. The well-characterized lineage-speciﬁ  c 
cell surface markers that deﬁ  ne the complex hier-
archical model of the hematopoietic system, includ-
ing hematopoietic stem cells, provided the clues 
for the ﬁ  rst elegant studies identifying cancer stem 
cells in acute myeloid leukemia
93 and more recently 
in gliomas.
94–97 Glioma stem cells (GSCs) represent 
a small fraction of the tumor cell population that 
are capable of asymmetric cell division into self-
renewing GSCs and differentiating daughter cells 
that can acquire different phenotypes, subsequently 
losing their multipotent ability. Their capacity for 47
Glioblastoma multiforme oncogenomics and signaling pathways
Clinical Medicine: Oncology 2009:3
limitless self-renewal and their ability to repopulate 
and maintain a heterogeneous tumor indicate that 
GSCs are a promising target for curative therapies. 
However, signiﬁ  cant fundamental questions still 
remain about these unique GSCs. A cell capable of 
initiating a glioma may not necessarily be the same 
cell responsible for long-term glioma self-renewal; 
therefore, there may exist subpopulations of “GSC 
initiators” and “GSC propagators.” The cell of 
origin for GSCs is still debated with evidence sup-
porting different theories.
98 These cells may arise 
from developmentally arrested neural progenitors 
or from dedifferentiated astrocytes. Heterogeneity 
within a glioma may not necessarily reﬂ  ect a stem 
cell origin of the glioma producing different phe-
notypes, but could be due to mutations inducing 
self-renewal properties in progenitor cells with 
more limited differentiation potential. Clearly, 
targeting GSCs with therapies poses new dilem-
mas. Theoretically, a GSC would normally be 
quiescent, entering the cell cycle only in response 
to external cues such as growth factors; therefore, 
quiescent GSCs would unlikely be vulnerable to 
classic treatments that preferentially target rapidly 
dividing cells. GSCs represent fundamentally 
unique glioma cells and as discussed below, they 
likely depend on genomic alterations and intracel-
lular signaling pathways that differ from non-GSC 
tumor cells. Therefore, these GSC may contribute 
to resistance to current therapies as well as future 
therapies that target genes and proteins that char-
acterize the bulk of the tumor mass. GSCs may 
also express high levels of drug export proteins, 
contributing to therapeutic resistance.
Despite the challenges, targeting GSCs is par-
ticularly attractive because of the universal pattern 
of recurrence in these tumors. Neurosurgeons can 
often remove over 90% of the visible tumor, but the 
cells that have migrated away from the visible tumor 
focus will proliferate and lead to the demise of the 
patient. There is circumstantial evidence that GSC 
may be related to these migrating glioma cells, so 
it is reasonable to assume that targeting GSCs will 
either control migrating cells from the primary 
focus or limit tumor growth at the secondary focus. 
Seen throughout all of oncology are the common 
genetic events and signaling pathways used in 
cancer cells as well as normal stem cells. Interest-
ingly, neural stem cells have the same tremendous 
capacity for migration as glioma cells, supporting 
the idea that some of the migrating glioma cells 
have GSC properties. If GSCs are found to arise 
from neural stem cells, then targeting GSC may 
indeed target the migrating tumor cells and lead to 
a cure for patients who can tolerate the successful 
treatment of their primary glioma focus. EGFR 
overexpression is sufﬁ  cient to confer migratory 
potential to neural progenitors supporting the theory 
that gliomas may originate in progenitors from the 
subventricular zone (SVZ).
99 These cells may rap-
idly migrate to more favorable areas for tumor 
proliferation, e.g. factors that support better neoan-
giogenesis.
Targeting GSC will likely have to rely on 
genomic or proteomic characteristics that differ 
from other glioma tumor cells. GSCs express imma-
ture antigens speciﬁ  c for neural stem and progeni-
tor cells, including the neuroﬁ  lament protein nestin, 
the glycoprotein CD133 (a.k.a. prominin-1), 
Musashi-1 and BMI-1.
94–96 These markers suggest 
the activation of similar developmentally regulated 
pathways.
100 CD133 has been the most prevalent 
marker for isolating GSCs from GBM.
97,101 CD133+ 
cells comprise 5%–30% of the tumor cell popula-
tion, and as few as 100 cells can reproduce tumors 
in animal models.
101 A marker of multipotent stem 
cells in blood and other tissues, much work remains 
to elucidate the role of CD133 in GSCs. Sonic 
hedgehog (SHH) and Notch (Fig. 1) are key regu-
lators of neural progenitors in development and 
have also been found to be altered or overexpressed 
in GSCs.
102 SHH has been best studied in the malig-
nant brain tumor, medulloblastoma. However, some 
evidence supports its role in GBM GSCs as well.
103 
SHH is a critical mitogen for medulloblastoma 
precursor cells. Hereditary loss of function muta-
tions in the SHH receptor Patched (PTCH) lead to 
constitutive activation of the SHH pathway and 
predisposition to medulloblastoma in Gorlin syn-
drome. The SHH pathway is intimately connected 
to cell cycling since it inactivates RB1, facilitating 
the over-expression of cell cycle regulators such as 
N-myc. Notch activation induces expression of 
downstream target genes, such as p53, and promotes 
neural stem cell growth.
104 It also is better studied 
in medulloblastoma where activating mutations 
lead to stem-like cells, but it has been implicated 
in GSCs as well. Clearly implicated in gliomagen-
esis, EGFR expression also plays a role in neural 
progenitor development and is speculated to con-
tribute directly to GSC maintenance.
Olig2 is expressed in myelinating oligodendrog-
lia, but is also in mitogen-treated “transit-amplifying 
cells” of the SVZ, the presumed site of most neural 48
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progenitor cells and a theorized site for the origin 
of gliomas.
105 Olig2 and Olig1 are basic-helix-loop-
helix transcription factors expressed in neural and 
oligodendrocyte precursors. Olig2 is almost univer-
sally found in NG2-positive glia and required for 
development of these cells.
106 NG2 is a Chondroitin 
sulfate proteoglycan that is thought to be another 
marker of oligodendrocyte progenitor cells. Olig2 
sustains a replication-competent state of neural 
progenitors
107 via suppression of p21.
108 There is 
much work to be done, but Olig2 and NG2 may be 
important markers and/or targets for oligodendro-
glioma stem cells.
There is some interaction between genes known 
to regulate stem cell proliferation and genetic lesions 
in malignant gliomas. Some of the most common 
lesions in malignant gliomas are loss-of-function 
mutations in p16
Ink4a and p19
ARF negative regulators 
of the RB signaling pathway. Gain-of-function 
mutations in CDK4 are seen, in GBM, activating 
the RB pathway.
109 Bmi1, a promoter of neural stem 
cell self-renewal and neural development, is 
expressed in most gliomas and promotes malig-
nancy in p16
Ink4a/p19
ARF double-null murine glio-
mas.
110 As already described, Olig2, a marker of 
oligodendroglia precursors, is expressed in 100% 
adult gliomas
111 and 100% of CD133 + glioma stem 
cells. Olig2 is required for tumor formation in 
p16
Ink4a/p19
ARF double null murine gliomas. Recent 
studies have conﬁ  rmed the extensively studied role 
of members of the TGF-β superfamily in morpho-
genesis and speciﬁ  cally brain development.
112 As 
described above, TGF-β may play a signiﬁ  cant role 
in GBM development as well.
Studies such as these strongly support the 
progenitor cell of origin theory for GSCs. It appears 
that there may be common genetic gatekeepers, 
such as Olig2 and SHH, for neurodevelopment 
and glioma formation. Developing targeted 
therapies may be developed to kill GSCs, but may 
also require sophisticated engineering in order to 
avoid harming normal stem cells. GSC may 
provide the clues to resistance of this deadly tumor 
to current therapies. Despite being sensitive to 
TMZ, the most common chemotherapy in GBM, 
CD133 + GSCs appear to be quite resistance to 
radiation therapy.
113,114
Summary and future hope
Perhaps the greatest mystery in understanding the 
oncogenomics of GBM is deciding how and when 
these genetic alterations and signaling cascades 
interact. Even though only a few speciﬁ  c pathways 
are consistently highlighted, there are undoubtedly 
complex interactions among them as well as with 
additional unknown players. Clearly, many if not 
most of these genetic events described do not occur 
in isolation. For example, LOH 10q is not only the 
most frequent genetic alteration, but typically 
occurs in the context of other genetic alterations.
2 
This suggests that LOH of 10q plus other genetic 
events create a genomic environment that collec-
tively contributes to the development of a majority 
of GBMs. Mutations of p53, p16
INK4a deletion, 
EGFR ampliﬁ  cation, and PTEN mutations show 
inverse associations with each other, except for a 
positive correlation between p16
INK4a deletion and 
EGFR ampliﬁ  cation.
2,115,116 Once a thorough road 
map for GBM oncogenomics is designed, it should 
aid in the development of more rational and more 
effective targeted therapies. Indeed, it is highly 
plausible that a cocktail of therapies targeting the 
major intersections in the roadmap for each indi-
vidual GBM will be required to effectively slow 
or halt this tumor.
The lack of signiﬁ  cant progress in GBM therapy 
is likely multifactorial, including a lack of oncoge-
nomic understanding, tremendous multi-drug 
resistance, radioresistance, insufﬁ  cient preclinical 
models, and a tenacious blood-brain barrier. Gene 
expression proﬁ  les and preclinical studies have 
elucidated many of the oncogenomic changes, but 
basic questions such as the GSC origin and the 
hierarchy of the oncogenomic events still remain 
elusive.
The current standard of care for GBM patients 
begins with gross total resection if possible, 
followed by concomitant radiotherapy (typically 
60 Gy in 2-Gy fractions) and TMZ chemotherapy 
(75 mg/m
2 for 42 days). This adjuvant therapy is 
repeated in a 5/28-day schedule for 5 cycles 
(150 mg/m
2) if tolerated. Surgery and radiotherapy 
have been mainstays in GBM treatment for decades 
with little modiﬁ  cation. TMZ, an alkylating agent, 
was only recently established in a randomized 
clinical trial as the standard of care chemotherapy, 
demonstrating a slight increase in overall survival 
from 12 to 15 months.
117
Our current exploration of aberrant molecular 
and cytogenetic pathways involved in GBM has 
led to numerous clinical trials testing more 
speciﬁ  c, molecular-based, therapies for this tumor. 
EGFR has been an attractive target, especially 49
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since it can trigger several downstream signaling 
pathways (PI3K/AKT/mTOR, Ras/Raf/MAPK, 
and PKC) and is abnormally activated in some 
manner in up to 60% of GBMs and 70% of all 
solid cancers. Targeting strategies have included 
monoclonal antibodies, bispecific antibodies, 
toxin-linked conjugates, vaccines, and small-
molecule tyrosine kinase inhibitors (TKIs). 
Phase II clinical trials with EGFR TKIs (ZD-1839, 
geﬁ  tinib; OSI-774, erlotinib) demonstrated some 
responses, but overall minimal improvement over 
historical controls in unselected patients.
118,119 
Because of the activation of mTOR due to the 
frequent loss of PTEN in GBM, mTOR inhibitors 
have also become exciting tools. The mTOR 
inhibitor CCI-779 (ester of the immunosuppres-
sive agent sirolimus [rapamycin]) did not show 
efﬁ  cacy as monotherapy, but may be applicable to 
combination therapies.
120 CCI-779 binds FKBP-12 
to form a complex that inhibits mTOR, resulting 
in cell-cycle arrest. The matrix metalloproteinase 
inhibitor marimastat has been combined with TMZ 
and demonstrated increased progression-free 
survival in GBM patients.
These examples of molecular-based targeted 
therapies being tested in clinical trials represent a 
new era in GBM therapeutics that bring hope to 
those afﬂ  icted with this fatal disease. With this 
enthusiasm for testing therapies based on speciﬁ  c 
GBM biology, we are entering an exciting era in 
dealing with this deadly tumor. Numerous other 
targeted therapies have gone through preclinical 
testing.
121 Unfortunately, we are still awaiting any 
major breakthroughs in clinical trials. Further 
unraveling of the critical genetic alterations that 
lead to the initiation and progression of GBM may 
be necessary for future therapies to work.
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